Suppliers / Zhejiang Cheng Yi Pharmaceutical

Zhejiang Cheng Yi Pharmaceutical

China Updated 9 July 2026

Zhejiang Cheng Yi Pharmaceutical is an API manufacturer based in China. It holds 4 active US drug master files across a filed portfolio of 4 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 7 March 2025 as VAI.

4
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 7 March 2025 VAI US FDA
  • 22 November 2019 VAI US FDA
  • 15 July 2016 VAI US FDA
  • 14 March 2014 VAI US FDA
  • 9 September 2010 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3004090742

What they file, and where

Molecule Regulators Docs
Azathioprine US FDA 1
Glucosamine US FDA 1
Mercaptopurine US FDA 1
Ribavirin US FDA 1

Also appears on these molecule pages

Azathioprine API Glucosamine API Ribavirin API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Zhejiang Cheng Yi Pharmaceutical

Does Zhejiang Cheng Yi Pharmaceutical hold a US DMF or a CEP?
Zhejiang Cheng Yi Pharmaceutical holds 4 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Zhejiang Cheng Yi Pharmaceutical FDA-registered?
One site operated by Zhejiang Cheng Yi Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Zhejiang Cheng Yi Pharmaceutical's last inspection go?
The most recent inspection on record closed on 7 March 2025 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 5 inspections are on file.
Where does Zhejiang Cheng Yi Pharmaceutical manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Zhejiang Cheng Yi Pharmaceutical make?
4 molecules are on record against Zhejiang Cheng Yi Pharmaceutical, including Azathioprine, Glucosamine, Mercaptopurine and Ribavirin. Each links through to that molecule's full manufacturer list.
Which regulators recognise Zhejiang Cheng Yi Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Cheng Yi Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 7 March 2025.

Comparable suppliers

Apitoria Pharma shares 1 molecule Matrix Pharmacorp shares 1 molecule Zydus Lifesciences shares 1 molecule Curia shares 1 molecule Raks Pharma shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates